Quantcast

Cryobanks India Begins an Era of Automation in Stem Cell Banking with Swiss Partner Biosafe

August 15, 2013

Cryobanks International India entered into an agreement with Biosafe S. A., Switzerland the industry leader providing an extremely stable platform for processing cord blood utilizing a closed-system technology named SEPAX®.

Gurgaon, Haryana (PRWEB) August 15, 2013

Cryobanks International India, a leader in umbilical cord blood stem cell banking In India, has entered into an agreement with Biosafe S. A., Switzerland, which is the industry leader providing an extremely stable platform for processing cord blood utilizing a closed-system technology named SEPAX®. The SEPAX® is a fully automated and sterile stem cell processing equipment that delivers higher yields than are possible using current manual technologies – up to 95%. This eliminates the variability in end-product yields possible due to differences in operator training and abilities. SEPAX® is currently utilized by more than 70% of the public cord blood banks registered with Netcord – the world’s leading organization for facilitating cord blood transplants by providing a channel through which potential patients and public cord blood banks can connect. This advanced technology with proven transplant track-record has been US-FDA approved, CE-marked and accepted by the Japan MHLW (Ministry of Health and Labor Welfare).

Umbilical cord blood is a rich source of stem cells and Cryobanks will facilitate the storage of the cord derived cells and tissue for any family looking to store them for a certain fee – these cells could be of great value to the family if any of them are struck down by blood cancer, thalassemia and requiring a bone marrow transplant. It is also expected that in the future other diseases can also be resolved using cord blood derived stem cells and tissue. A representative of Cryobanks stated that “Expectant parents can save the cord blood and tissue of their baby for a period of 21 years with a small investment that has life-saving potential if the need ever arises. Our bank stores the stem cells in advanced nitrogen vapour tanks at -196 degrees Celsius and has invested in comprehensive monitoring, safety and redundancy systems.

About Cryobanks International India:

Cryobanks International India a JV between Lifeforce Cryobanks International USA and RJ Corp founded in 2006. The company is focused on providing high-quality umbilical cord blood stem cell processing, and storage for both private and public donation purposes. Based at Gurgaon with a network of collection and marketing staff in most of the towns of India, it provides a high-end processing and storage facility which is approved by several International certification agencies. Cryobanks India has also spread beyond the Indian shores to Thailand, UAE, Nepal, Bangladesh and East Africa making it the only Indian Cord Blood bank operating in the International Market.

LifeForce Cryobanks International USA, a pioneer in the collection, isolation, and storage technologies for cord blood stem cells, is located in Altamonte Springs, Florida. The company is focused on providing high-quality umbilical cord families that wish to privately store their baby's precious stem cells and a Public Cord Blood Donation Program for those who prefer to donate.

About Biosafe S. A., Switzerland

The Biosafe S.A. headquarters in Switzerland houses research and development, manufacturing and marketing. The subsidiary Biosafe Asia-Pacific Limited services customers in Hong Kong and China directly and actively supports their distributor network in the Asia-Pacific region. To date, over 800 Biosafe SEPAX® systems have been installed in stem cell laboratories and hospitals in more than 50 countries worldwide. The SEPAX® system is the industry standard in automated adult stem cell processing and the preferred technology for the majority of the world’s public and private cord blood banks.

For the original version on PRWeb visit: http://www.prweb.com/releases/cryobanks/stem-cells/prweb11026910.htm


Source: prweb



comments powered by Disqus